key: cord-1040993-57t31eus
authors: Scott, Lesley E.; Noble, Lara D.; Singh-Moodley, Ashika; Kahamba, Trish; Hardie, Diana R.; Preiser, Wolfgang; Stevens, Wendy S.
title: Challenges and complexities in evaluating severe acute respiratory syndrome coronavirus 2 molecular diagnostics during the COVID-19 pandemic
date: 2022-04-26
journal: Afr J Lab Med
DOI: 10.4102/ajlm.v11i1.1429
sha: f4d03dd5237b66a263cbb1c2bc944b246f79fc3f
doc_id: 1040993
cord_uid: 57t31eus

nan

The entire pathology value chain needs to be considered when selecting suitable NAATs. Each step contributes to meaningful and valid test results: patient sampling, specimen type, specimen collection and handling (stability), viral RNA purification, amplification and detection, and result interpretation ( Figure 1 ). Specimen collection and handling challenges include swab type, collection site, collection and pre-treatment methods, and transport. Swabs are manufactured from different materials (cotton, nylon, polyester, rayon and foam) and may be spun or flocked. 10, 11 Thus, swabs differ in absorption properties, viral capture and release. Swab shafts may be made from wood, plastic or aluminium, and some of these materials are incompatible with certain collection and laboratory techniques (e.g. wooden shafts are unsuitable for paediatric sampling and may inhibit NAAT). 10 Commonly used swab collection sites are the nasopharynx, mid-turbinate region, nasal cavity or oropharynx, but the method used for a particular specimen is often not documented or made known to a testing laboratory. Alternative specimen types include saliva, gargle, sputum and faecal material. Furthermore, multiple swabs may be combined in a single testing vial. After collection, the swabs may be transported dry or in plain saline, phosphate-buffered saline, or various preservation media (e.g. viral transport media). The medium may vary in volume (1 mL -3 mL), impacting viral concentration. Specimens are transported at 2 °C -8°C or at ambient temperature, which, in some settings, means high humidity and temperature. Certain testing laboratories insist on inactivation of viral swabs for biosafety, which could include chemical or heat pre-treatment. ) or combination of genes targeted by NAAT are inconsistent. These have been reported to affect overall assay sensitivity and specificity, 13, 14 and may also be impacted by viral genetic evolution that can affect gene targets. 15 Furthermore, there is the complex layer of different diagnostic algorithms implemented within countries that often change over time. For example, some settings report HCW, healthcare worker; LIS, laboratory information system; PCR, polymerase chain reaction; RNA, ribonucleic acid. 21 This may be based on WHO recommendations, or, under emergency use, current in-county methodology already approved for standard of care (SOC). In our case, at least seven SOC technologies are in use to report patient results across South Africa, and residual specimens from these assays were available for challenge panels. The goal of performance evaluation is to determine whether a new method or technology is as good as SOC and use thereof will not alter patient care. However, this does pose a challenge if SOC specimens are in a different format or RNA degrades during specimen storage. Our group obtained institutional review board approval to use residual patient specimens for evaluations with an informed consent waiver. Where fresh or paired specimens were needed, a full clinical trial was required with informed consent, which increased the time needed and cost of evaluations.

Once an evaluation is completed, method comparison involves determining accuracy (sensitivity and specificity) or agreement, precision (reproducibility), linearity and limit of detection. Recommendations are made based on analytical performance, as well as ease of use. In the absence of acceptance criteria guidelines, we investigated these parameters for an initial 24 assays using a standardised evaluation protocol approach as described in Table 1 .

Over and above the already mentioned complexities and challenges, it became apparent that single method comparison acceptance criteria might not be applicable to all assays. We identified four types or categories of assays submitted for evaluation: (1) closed systems (incorporating RNA extraction and NAAT), (2) standalone PCR kits to be performed off already purified RNA, (3) direct lyse-to-PCR, where no frontend RNA purification or extraction is available or where there is a need for rapid testing, and (4) standalone RNA extraction or purification kits. The 24 assays were among groups 1 (n = 9), 2 (n = 12) and 3 (n = 3), with the predominant viral gene targets being N (35.0%), followed by ORF1ab (25.0%), E (20%), S (10.0%) and RdRp (10.0%). A sensitivity score of > 90% was achieved by 62.5% (15/24) of assays and > 95% sensitivity achieved by 37.5% (9/24) compared to SOC. Those that employ direct lyse-to-PCR (group 3) were below the acceptance criteria by at least a 20% drop in median sensitivity (72.0%) compared to the median sensitivity in group 1 (95%) and group 2 (92.0%). The clinical specimens used in these assays' evaluation panels covered a range in SARS-CoV-2 VL, with a median target Ct = 27. Group 3 performed well on specimens with high VL (Ct < 30), and hence another challenge is not only in the choice of range in clinical specimens being evaluated, but potentially the need to apply different acceptance criteria, bearing in mind that group 3 assays are designed for use where no front-end RNA extraction (or rapid) system is available. The reduced sensitivity needs to be weighed against the rapid availability of a result which would likely identify patients who are newly symptomatic and at the height of being infectious. Therefore, the diagnostic dilemma facing regulators and end users could be 'no available test' or 'specimens routed a further distance (with ensuing longer TAT) to a testing laboratory with access to front-end RNA extraction technology', or a 'less sensitive test with potentially shorter TAT and greater clinical relevance'.

Selecting clinically relevant, laboratory-compatible and wellperforming SARS-CoV-2 NAAT assays or systems for patient care is complex and subject to several challenges, as also highlighted elsewhere. 9, 22 Current evaluation protocols are not robustly performed under emergency circumstances, 21 and performance acceptance criteria and technology placement may require flexibility. 23 Assays themselves have also improved with time. Added layers of complexity that we experienced were donated tests that did not always follow required regulatory pathways prior to implementation, and suppliers requesting evaluation from multiple laboratories in the hope of improving their performance score. However, having a new test ready for use is only half the battle, and still requires rapid implementation and scale-up, with further factors requiring investigation such as cost, supply chain management, training, quality assessment, interfacing to existing laboratory information systems, compatibility to existing testing landscapes, continuous quality monitoring and post-market surveillance, to name a few. An overall sensitivity > 95% shows an assay with good performance in identifying SARS-CoV-2 at all ranges of viral concentration and therefore patient's course of infection An overall sensitivity > 90% shows an assay with acceptable performance identifying SARS-CoV-2 100% specificity Assay robustness Number of errors, invalids < 3% invalid rate, < 1% error Ease of use Based on a target product profile (e.g. www.sahpra.org.za 24 and, more recently, WHO 7 )

Based on a target product profile (e.g. www.sahpra.org.za 24 and, more recently, WHO 7 )

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

A novel coronavirus from patients with pneumonia in China

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 -11

COVID-19 dashboard

COVID-19 test directory

Covid-19 molecular diagnostic testing -Lessons learned

SARS-CoV-2 molecular assay evaluation results

Molecular diagnosis of COVID-19: Challenges and research needs

Considerations for diagnostic COVID-19 tests

Guidance COVID-19: Guidance on alternative swab types and transport media

Comparison of three nasopharyngeal swab types and the impact of physiochemical properties for optimal SARS-CoV-2 detection

The implementation of a rapid sample preparation method for the detection of SARS-CoV-2 in a diagnostic laboratory in South Africa 2020

Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2

Use of whole genome sequencing data for a first in silico specificity evaluation of the RT-qPCR assays used for SARS-CoV-2 detection

World Health Organization. Tracking SARS-CoV-2 variants

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

A systematic review of the clinical utility of cycle threshold values in the context of COVID-19

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

European Centres for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom

Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

The estimation of diagnostic accuracy of tests for COVID-19: A scoping review

Current approach in laboratory testing for SARS-CoV-2

Rethinking Covid-19 test sensitivity -A strategy for containment

South African Health Products Regulatory Authority. MD018: Specification criteria for COVID-19 molecular test kits

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article. 

The use of residual blood, swab and universal transport medium specimens for research and development of molecular and serology assays for SARS-CoV-2 was approved